Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00684034
Other study ID # 2007-A01179-44
Secondary ID 2007-38
Status Completed
Phase N/A
First received May 21, 2008
Last updated August 27, 2014
Start date June 2008
Est. completion date April 2012

Study information

Verified date August 2014
Source Assistance Publique Hopitaux De Marseille
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

The influence of hemodialysis on oxidative stress, endothelial activation, inflammation and on the redox state of lymphocytes should be clarified as well as the putative relationships between all these parameters.


Description:

Up to now, no anti-oxydative treatment has been able to reduce the mortality of the patients with Kidney Failure. Thus it is necessary to have a better knowledge of oxydative stress mechanisms in patients with KF in order to find more efficacious treatments. The influence of hemodialysis upon oxidative stress is not well known.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date April 2012
Est. primary completion date April 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- 18 and 80 years old man or woman dialysing at least 3 times a week for at least 6 months and having no residual renal function

- Rate of haemoglobin > 11 g / dl

- Clinically stable patient that is having had no considerable event (cardiovascular problem, infection, surgical operation) with the exception of angioplasty of fistula or prosthesis vascular, in the previous 3 months the entrance to the study

- Patient capable of understanding and of following the essay, in particular knowing how to read the note of information.

Exclusion Criteria:

- Pregnant woman

- Treatment by corticoids or immunosuppresseurs

- hemopathy sly

- chronic cancer or infection in evolution

- Cardiovascular event (infarct, unstable angor, coronary bypasses, confusions of the rhythm, AVC, amputation) or infectious (blood-poisoning, pneumopathie, meningitis) or surgical operation in the previous 3 months the inclusion in the study.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Other:
Sampling of blood
A sampling of blood will be made
Sampling of blood
A sampling of bood will be made before the dialysis
Sampling of blood
A sampling of blood will be made.

Locations

Country Name City State
France Hopital de la Conception- Service de Néphrologie et de transplantation rénale Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary This study should allow to clarify the redox state some plasma by quantification of thiols membranous on the surface of lymphocytes at the hemodialysis and insufficient renal chronic not dialysed patients. 48 months Yes
Secondary This study should allow to estimate in a forward-looking longitudinal plan the possible involvement of the parameters of the redox state and the morbidity and the cardiovascular and global mortality in 2 years in 2 studied populations. 48 months Yes
See also
  Status Clinical Trial Phase
Completed NCT00968877 - Vitamin D and Chronic Renal Insufficiency Phase 3
Terminated NCT00701714 - Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients Phase 3
Completed NCT00998972 - N-acetyl-cysteine (NAC) and Kidney Graft Function Phase 3
Completed NCT00716573 - Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure Phase 4
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02203084 - Social Determinants in Chronic Disease in British Columbia N/A
Recruiting NCT02147782 - Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00095056 - An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) Phase 3
Completed NCT00223548 - MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application Phase 2
Completed NCT01574157 - Investigations of the Optimum Serum Bicarbonate Level in Renal Disease. N/A
Active, not recruiting NCT02751099 - Bone and Cardiovascular Disease After Kidney Transplant
Recruiting NCT02002585 - Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease Phase 2
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT01252810 - Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure Phase 2
Completed NCT00792857 - Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) Phase 1
Completed NCT00888069 - Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects Phase 1
Completed NCT00369733 - STAAR-3 Clinical Study Phase 4
Recruiting NCT06362759 - A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP Phase 2